Publications
Atypical Hemolytic Uremic Syndrome
Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y, Walport MJ, Cook HT, Botto M. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9649-54.
The Complement Alternative Pathway
The spectrum of complement alternative pathway-mediated diseases. Holers VM. Immunological Reviews. 2008;223:300-316.
Neurology
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, Rother RP, Plomp JJ, Willison HJ. Brain. 2008 May;131(Pt 5):1197-208.
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ. J Immunol. 2007 Dec 15;179(12):8562-7.
PNH
Expression of Recombinant Transmembrane CD59 in Paroxysmal Nocturnal Hemoglobinuria B Cells Confers Resistance to Human Complement. Rother RP, Rollins SA, Mennone J, Chodera A, Fidel SA, Bessler M, Hillmen P, and Squinto SP. Blood, Vol84, No 8 (October 15). 1994: pp 2604-2611.
Kelly RJ, et al. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival. Blood. 2011;117(25):6786-6792
See additional publications on PNH
STEC-HUS
Complement Bloackade in Severe Shiga-Toxin-Associated HUS. Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, et al. Complement blockade in severe Shigatoxin—associated HUS. N Engl J Med 2011. DOI: 10.1056/NEJMc1100859.
Transplantation
C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Rother RP, Arp J, Jiang J, Ge W, Faas SJ, Liu W, Gies DR, Jevnikar AM, Garcia B, Wang H. Am J Transplant. 2008 Jun;8(6):1129-42.
Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. Wang H, Arp J, Liu W, Faas SJ, Jiang J, Gies DR, Ramcharran S, Garcia B, Zhong R, Rother RP. J Immunol. 2007 Oct 1;179(7):4451-63.
Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Wang H, Jiang J, Liu W, Kubelik D, Chen G, Gies D, Garcia B, Zhong R, Rother RP. Transplantation. 2005 May 15;79(9):1121-7.
Anti-C5 antibodies
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Mol Immunol. 1996 Dec;33(17-18):1389-401.
In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Evans MJ, Rollins SA, Wolff DW, Rother RP, Norin AJ, Therrien DM, Grijalva GA, Mueller JP, Nye SH, Squinto SP, et al. Mol Immunol. 1995 Nov;32(16):1183-95.
Complement-specific antibodies: designing novel anti-inflammatories. Matis LA, Rollins SA. Nat Med. 1995 Aug;1(8):839-42.